Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group.
Darpö B, Edvardsson N. Darpö B, et al. J Cardiovasc Pharmacol. 1995 Aug;26(2):198-206. doi: 10.1097/00005344-199508000-00004. J Cardiovasc Pharmacol. 1995. PMID: 7475043 Clinical Trial.
Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.
Houltz B, Darpö B, Edvardsson N, Blomström P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K. Houltz B, et al. Among authors: darpo b. Pacing Clin Electrophysiol. 1998 May;21(5):1044-57. doi: 10.1111/j.1540-8159.1998.tb00150.x. Pacing Clin Electrophysiol. 1998. PMID: 9604236
Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation.
Darpö B, Almgren O, Bergstrand R, Bäärnhielm C, Gottfridsson C, Sandstedt B, Edvardsson N. Darpö B, et al. J Cardiovasc Pharmacol. 1995 May;25(5):681-90. doi: 10.1097/00005344-199505000-00001. J Cardiovasc Pharmacol. 1995. PMID: 7630145 Clinical Trial.
Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings.
Darpö B, Vallin H, Almgren O, Bergstrand R, Insulander P, Edvardsson N. Darpö B, et al. J Cardiovasc Pharmacol. 1995 Oct;26(4):530-40. doi: 10.1097/00005344-199510000-00005. J Cardiovasc Pharmacol. 1995. PMID: 8569212 Clinical Trial.
131 results